Article Information
History
- May 19, 2022.
Article Versions
- Version 1 (January 19, 2022 - 23:42).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- 1Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
- ↵*Corresponding author: James M. Wilson, MD, PhD, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, 125 South 31st Street, Suite 1200, Philadelphia, PA 19104, USA, Phone: 215-573-9020; Fax: 215-494-5444, E-mail: wilsonjm{at}upenn.edu
Posted May 19, 2022.
High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
